https://www.fiercebiotech.com/biotech/astellas-owned-xyphos-offers-800m-kelonias-vivo-delivery-know-how
Astellas buying up, pre-clinic.
Astellas bought Xyphos back in 2019 for $120 million upfront with more than $500 million in biobucks available.
Xyphos linking arms with Kelonia in a research and licensing deal worth north of $800 million. Kelonia will receive a $40 million upfront payment for its work and could snag another $35 million should Xyphos buy into the second. The total amount of milestone and contingency payments is close to $800 million.
https://www.fiercebiotech.com/biotech/astellas-owned-xyphos-offer...
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
-0.002(6.90%) |
Mkt cap ! $23.12M | |||
| Open | High | Low | Value | Volume |
| 2.9¢ | 2.9¢ | 2.7¢ | $14.49K | 518.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1378548 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 158093 | 2 |
View Market Depth
| Last trade - 15.59pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.8¢ |
Change
-0.002 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 2.8¢ | 2.8¢ | 2.8¢ | 252061 | ||
| Last updated 15.47pm 06/05/2024 ? | |||||
| CHM (ASX) Chart |